Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ApproaCH: TransCon CNP in Children With Achondroplasia
NCT05598320Phase 3Completed
- Sponsor
- Ascendis Pharma
- Start
- Mar 2023
- Primary completion
- Aug 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
A Phase 3 trial of navepegritide in achondroplasia (ACH), sponsored by Ascendis Pharma. Started Mar 2023; status: completed.
02
Drugs
navepegritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT05598320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05598320.